Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
News | November 18, 2020
We’re happy to announce that we’ve received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program (MDSAP)!
The MDSAP is a stringent audit process that allows for a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer that, in addition to ISO13485:2016, satisfies the relevant requirements of the regulatory authorities participating in the program, including those in Canada, the United States, Brazil, Australia and Japan. Read more in today’s press release:
Stockholm, November 18, 2020 – Devyser, Swedish molecular diagnostics company, is pleased to announce that it has received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program (MDSAP).
The MDSAP is a stringent audit process that allows for a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer that, in addition to ISO13485:2016, satisfies the relevant requirements of the regulatory authorities participating in the program, including those in Canada, the United States, Brazil, Australia and Japan.
"Achieving the MDSAP certification confirms our ongoing commitment to maintaining the highest quality assurance standards within the In Vitro Diagnostic Medical Devices (IVD). The certification provides compliance in new jurisdictions enabling great potential for future market expansion and growth"
Says Fredrik Alpsten, CEO at Devyser Diagnostics AB.
"Delivering products that meet our customers’ high expectations is at the core of our business. The MDSAP certification is yet another token of this commitment, an achievement made possible by the entire Devyser staff and their unwavering focus on quality"
Says Olle Myrberg, Head of Quality Assurance at Devyser.
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More